Drug Database · Clinicians

Isoflurane

Brands (6) Evorane, Florane, Iso-floe…Show all

US brand (reference label): FORANE; not a Philippine-registered brand.

General Anesthetic US FDA class
General anesthetic (halogenated hydrocarbon) PH FDA category

Rx · Prescription drug6 PH productsPNF-listed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 3d30eb8d-a62e-475f-926b-78ba63bee9c8, version date December 9, 2024 (FORANE · Baxter Healthcare Corporation). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • FORANE (isoflurane, USP) may be used for induction and maintenance of general anesthesia.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE FORANE (isoflurane, USP) may be used for induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia. FORANE, a general anesthetic, is an inhalation agent indicated for induction and maintenance of general anesthesia. (1)

Contraindications

4 CONTRAINDICATIONS FORANE is contraindicated in patients:

  • in whom general anesthesia is contraindicated.
  • with known sensitivity to FORANE or to other halogenated agents [see Warnings and Precautions (5.3)].
  • with known or suspected genetic susceptibility to malignant hyperthermia [see Warnings and Precautions (5.1), Clinical Pharmacology (12.5)].
  • with a history of confirmed hepatitis due to a halogenated inhalational anesthetic or a history of unexplained moderate to severe hepatic dysfunction (e.g., jaundice associated with fever and/or eosinophilia) after anesthesia with isoflurane or other halogenated inhalational anesthetics.
  • Patients in whom general anesthesia is contraindicated (4)
  • Patients with known sensitivity to FORANE or other halogenated agents (4)
  • Patients with known or suspected genetic susceptibility to malignant hyperthermia (4)
  • Patients with a history of confirmed hepatitis due to a halogenated inhalational anesthetic or a history of unexplained moderate to severe hepatic dysfunction (e.g., jaundice associated with fever and/or eosinophilia) after anesthesia with FORANE or other halogenated inhalational anesthetics (4)
US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

  • FORANE should be administered only by persons trained in the administration of general anesthesia. FORANE should only be delivered using a vaporizer specifically designed and designated for use with isoflurane. (2)
  • The administration of general anesthesia must be individualized and titrated based on the patient’s age and clinical status. (2)
2.1 Important Dosage and Administration Information

2.1 Important Dosage and Administration Information FORANE should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. FORANE is administered by inhalation.

FORANE should be delivered from a vaporizer specifically designed for use with FORANE. Dosage for induction and maintenance must be individualized and titrated to the desired effect according to the patient’s age and clinical status. With the exception of neonates, the minimum alveolar concentration (MAC) of isoflurane decreases with increasing patient age.

Nitrous oxide decreases the MAC of FORANE (see Table 1). Opioids decrease the MAC of FORANE [see Drug Interactions (7)]. FORANE potentiates the muscle relaxant effect of all neuromuscular blockers and decreases the required doses of neuromuscular blocking agents [see Drug Interactions (7)]. The dose should be adjusted accordingly.

All patients anesthetized with FORANE should be continually monitored (e.g., monitoring of the electrocardiogram, blood pressure, oxygen saturation, and end tidal CO2). FORANE is a profound respiratory depressant. Excessive respiratory depression may be related to depth of anesthesia and respond to decreasing the inspired concentration of FORANE.

The depressant effect is accentuated by concurrent use of opioids and other respiratory depressants. Respiration should be closely monitored and assisted or controlled ventilation employed when necessary.

2.2 Premedication

2.2 Premedication Premedication should be selected according to the need of the individual patient, taking into account that secretions are weakly stimulated by FORANE, and the heart rate tends to be increased.

2.3 Induction

2.3 Induction Induction with FORANE in oxygen or in combination with oxygen-nitrous oxide mixtures may produce coughing, breath holding, laryngospasm and bronchospasm, which increases with the concentration of isoflurane. These difficulties may be avoided by the use of a hypnotic dose of an ultra-short-acting barbiturate.

Inspired concentrations of 1.5 to 3% isoflurane usually produce surgical anesthesia in 7 to 10 minutes.

2.4 Maintenance

2.4 Maintenance FORANE MAC values according to age are shown below: Table 1: Effect of Age on Minimum Alveolar Concentration of FORANE Age Average MAC Value In 100% Oxygen Average MAC Value In 30% Oxygen and 70% N 2 O Preterm neonates less than 32 weeks gestational age 1.28% Preterm neonates 32-37 weeks gestational age 1.41% 0-1 month 1.60% 1-6 months 1.87% 6-12 months 1.80% 1-5 years 1.60% 6-10 years 1.45% 11-18 years 1.38% 19-30 years 1.28% 0.56% 31-55 years 1.15% 0.50% 55-83 years 1.05% 0.37% Dosage for induction and maintenance must be individualized and titrated to the desired effect according to the patient’s age and clinical status. Surgical levels of anesthesia may be sustained with a 1 to 2.5% concentration when nitrous oxide is used concomitantly.

An additional 0.5 to 1% may be required when isoflurane is given using oxygen alone. If added relaxation is required, supplemental doses of neuromuscular blocking agents may be used. The level of blood pressure during maintenance is an inverse function of FORANE concentration in the absence of other complicating problems.

Excessive decreases may be due to depth of anesthesia and in such instances may be corrected by lightening anesthesia. FORANE causes a dose-dependent reduction in systemic vascular resistance and blood pressure. Particular care must be taken when selecting the dosage for patients who are hypovolemic, hypotensive, or otherwise hemodynamically compromised, e.g., due to concomitant medications.

FORANE markedly increases cerebral blood flow at deeper levels of anesthesia to produce a transient increase in intracranial pressure. In patients with or at risk for elevations of intracranial pressure (ICP), administer isoflurane in conjunction with ICP-reducing strategies, as clinically appropriate.

2.5 Use in Patients with Coronary Artery Disease

2.5 Use in Patients with Coronary Artery Disease Regardless of the anesthetics employed, maintenance of normal hemodynamics is important to the avoidance of myocardial ischemia in patients with coronary artery disease. FORANE can cause dose-dependent coronary vasodilation and has been shown to divert blood from collateral-dependent myocardium to normally perfused areas in an animal model (“coronary steal”).

The extent to which coronary steal occurs in patients with steal-prone coronary anatomy is unclear. Monitor for signs of inadequate myocardial perfusion via hemodynamic monitors (e.g., ECG, blood pressure) during isoflurane administration. Consider additional cardiac monitoring in patients with known coronary artery disease, as clinically necessary.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use During the induction of anesthesia, saliva flow and tracheobronchial secretion can increase and can be the cause of larynogospasm, particularly in children. Published juvenile animal studies demonstrate that the administration of anesthetic and sedation drugs, such as FORANE, that either block NMDA receptors or potentiate the activity of GABA during the period of rapid brain growth or synaptogenesis, results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis.

Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately 3 years of age in humans. In primates, exposure to 3 hours of ketamine that produced a light surgical plane of anesthesia did not increase neuronal cell loss, however, treatment regimens of 5 hours or longer of isoflurane increased neuronal cell loss.

Data from isoflurane-treated rodents and ketamine-treated primates suggest that the neuronal and oligodendrocyte cell losses are associated with prolonged cognitive deficits in learning and memory. The clinical significance of these nonclinical findings is not known, and healthcare providers should balance the benefits of appropriate anesthesia in pregnant women, neonates, and young children who require procedures with the potential risks suggested by the nonclinical data [see Warnings and Precautions (5.8), Nonclinical Toxicology (13.2)].

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use The minimum alveolar concentration (MAC) of isoflurane decreases with increasing patient age. The dose should be adjusted accordingly [see Dosage and Administration (2.4)].

Administration

2.1 Important Dosage and Administration Information FORANE should be administered only by persons trained in the administration of general anesthesia. Facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment, and circulatory resuscitation must be immediately available. FORANE is administered by inhalation. FORANE should be delivered from a vaporizer specifically designed for use with FORANE. Dosage for induction and maintenance must be individualized and titrated to the desired effect according to the patient’s age and clinical status. With the exception of neonates, the minimum alveolar concentration (MAC) of isoflurane decreases with increasing patient age. Nitrous oxide decreases the MAC of FORANE (see Table 1 ). Opioids decrease the MAC of FORANE [see Drug Interactions (7) ] . FORANE potentiates the muscle relaxant effect of all neuromuscular blockers and decreases the required doses of neuromuscular blocking agents [see Drug Interactions (7) ] . The dose should be adjusted accordingly. All patients anesthetized with FORANE should be continually monitored (e.g., monitoring of the electrocardiogram, blood pressure, oxygen saturation, and end tidal CO2). FORANE is a profound respiratory depressant. Excessive respiratory depression may be related to depth of anesthesia and respond to decreasing the inspired concentration of FORANE. The depressant effect is accentuated by concurrent use of opioids and other respiratory depressants. Respiration should be closely monitored and assisted or controlled ventilation employed when necessary.

US FDA label

Dosage forms

Registered products in the Philippines

6 products registered with the Food and Drug Administration (FDA) Philippines list Isoflurane as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products6
Philippine FDA-registered products for Isoflurane
Package insert
EvoraneIsoflurane
100% v/v Volatile Liquid For InhalationUSP Type III Amber Glass Bottle with Purple HDPE Lantern Ring at the Neck and Aluminum Screw Cap with LDPE Liner x 250 mL (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
AMB HK Enterprises Inc.
DRP-11353
Mar 3, 2027
FloraneIsoflurane
100% Liquid For Inhalation250-mL Polyethylene naphthalate (PEN) Amber Bottle with Snap-type Uni Adaptor x 100 mL (Box of 1's); 250-mL Polyethylene naphthalate (PEN) Amber Bottle with Snap-type Uni Adaptor x 250 mL (Box of 1's)
Rx
SINGAPORE PHARMAWEALTH LIFESCIENCES, INC.Philippines
ENDURE MEDICAL, INC.Importer: N/ATrader: N/A
DR-XY34988
Oct 5, 2031
Iso-floeIsoflurane
100% v/v Volatile Liquid for InhalationUSP Type III Amber Glass Bottle with Purple HDPE Lantern Ring at the Neck and Aluminum Screw Cap with LDPE Liner x 250 mL (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc
DRP-11353-01
Mar 3, 2032
IsoflurizzIsoflurane
100 % v/v Liquid for Inhalation250 mL USP III Amber Glass Vial with purple HDPE ring and aluminum cap with LDPE liner (Box of 1's)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Amson PharmaceuticalsImporter: Sahar International Trading, Inc.Trader: Betterway Pharmaceutical Group (HK) Limited
DRP-15018-01
Jan 20, 2030
IsoraneIsoflurane
100% v/v Liquid InhalationType III Amber glass Bottle with black phenol screw cap and polyethylene cone x 100mL (Box of 1's) (Box of 1's)
Rx
Piramal Pharma LimitedIndia
I.E. Medica, Inc.
DRP-971
Jul 7, 2031
SoraneIsoflurane
100% v/v Liquid for Inhalation250mL USP III Amber Glass Vial with purple HDPE ring and aluminum cap with LDPE liner (Box of 1 vial) (Box of 1 vial)
Rx
Lunan Better Pharmaceutical Co., Ltd.China
Sahar International Trading, Inc.Trader: Betterway Pharmaceutical Group (Hk) Limited
DRP-15018
Jan 20, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Isoflurane is a clear, colorless, stable liquid containing no additives or chemical stabilizers, 100% isoflurane. Liquid (stable): 100% (3)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Malignant Hyperthermia: Malignant hyperthermia may occur, especially in individuals with known or suspected susceptibility based on genetic factors or family history. Discontinue triggering agents, administer intravenous dantrolene sodium, and apply supportive therapies. (5.1)
  • • Perioperative Hyperkalemia: Perioperative hyperkalemia may occur. Patients with latent or overt neuromuscular disease, particularly with Duchenne muscular dystrophy, appear to be most vulnerable. Early, aggressive intervention is recommended. (5.2)
  • • Hepatic Reactions: May cause sensitivity hepatitis in patients sensitized by previous exposure to halogenated anesthetics. Approach repeated anesthesia with caution. (5.3)
  • • Hypersensitivity Reactions: Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with FORANE. (5.4)
  • • Abortions: Increased blood loss comparable to that seen with halothane has been observed in patients undergoing abortions. (5.5)
  • • QT Prolongation: Carefully monitor cardiac rhythm when administering FORANE to susceptible patients. (5.6)
  • • Interactions with Desiccated Carbon Dioxide (CO 2) Absorbents: May react with desiccated CO 2 absorbents to produce carbon monoxide. Replace desiccated CO 2 absorbent before administration of FORANE. (5.7)
  • • Pediatric Neurotoxicity: In developing animals, exposures greater than 3 hours cause …
5.1 Malignant Hyperthermia

5.1 Malignant Hyperthermia In susceptible individuals, volatile anesthetic agents, including FORANE, may trigger malignant hyperthermia, a skeletal muscle hypermetabolic state leading to high oxygen demand. Fatal outcomes of malignant hyperthermia have been reported. The risk of developing malignant hyperthermia increases with the concomitant administration of succinylcholine and volatile anesthetic agents.

FORANE can induce malignant hyperthermia in patients with known or suspected susceptibility based on genetic factors or family history, including those with certain inherited ryanodine receptor (RYR1) or dihydropyridine receptor (CACNA1S) variants [see Contraindications (4), Clinical Pharmacology (12.5)]. Signs consistent with malignant hyperthermia may include hyperthermia, hypoxia, hypercapnia, muscle rigidity (e.g., jaw muscle spasm), tachycardia (e.g., particularly that unresponsive to deepening anesthesia or analgesic medication administration), tachypnea, cyanosis, arrhythmias, hypovolemia, and hemodynamic instability.

Skin mottling, coagulopathies, and renal failure may occur later in the course of the hypermetabolic process. Successful treatment of malignant hyperthermia depends on early recognition of the clinical signs. If malignant hyperthermia is suspected, discontinue all triggering agents (i.e., volatile anesthetic agents and succinylcholine), administer intravenous dantrolene sodium, and initiate supportive therapies.

Consult prescribing information for intravenous dantrolene sodium for additional information on patient management. Supportive therapies include administration of supplemental oxygen and respiratory support based on clinical need, maintenance of hemodynamic stability and adequate urinary output, management of fluid and electrolyte balance, correction of acid base derangements, and institution of measures to control rising temperature.

5.2 Perioperative Hyperkalemia

5.2 Perioperative Hyperkalemia Use of inhaled anesthetic agents has been associated with rare increases in serum potassium levels that have resulted in cardiac arrhythmias and death in pediatric patients during the postoperative period. Patients with latent as well as overt neuromuscular disease, particularly Duchenne muscular dystrophy, appear to be most vulnerable.

Concomitant use of succinylcholine has been associated with most, but not all, of these cases. These patients also experienced significant elevations in serum creatinine kinase levels and, in some cases, changes in urine consistent with myoglobinuria. Despite the similarity in presentation to malignant hyperthermia, none of these patients exhibited signs or symptoms of muscle rigidity or hypermetabolic state.

Early and aggressive intervention to treat the hyperkalemia and resistant arrhythmias is recommended, as is subsequent evaluation for latent neuromuscular disease.

5.3 Hepatic Reactions

5.3 Hepatic Reactions Cases of mild, moderate and severe postoperative hepatic dysfunction or hepatitis with or without jaundice, including fatal hepatic necrosis and hepatic failure, have been reported with FORANE. Such reactions can represent hypersensitivity hepatitis, a known risk of exposure to halogenated anesthetics, including FORANE.

As with other halogenated anesthetic agents, FORANE may cause sensitivity hepatitis in patients who have been sensitized by previous exposure to halogenated anesthetics [see Contraindications (4)]. Clinical judgment should be exercised when FORANE is used in patients with underlying hepatic conditions or under treatment with drugs known to cause hepatic dysfunction [see Contraindications (4)].

As with all halogenated anesthetics, repeated anesthetics within a short period of time may result in increased effects, particularly in patients with underlying hepatic conditions, or additive effects in patients treated with drugs known to cause hepatic dysfunction. Evaluate the need for repeated exposure in each individual patient and adjust the dose of FORANE based on signs and symptoms of adequate depth of anesthesia if repeated exposure in a short period of time is clinically indicated.

5.4 Hypersensitivity Reactions

5.4 Hypersensitivity Reactions Allergic-type hypersensitivity reactions, including anaphylaxis, have been reported with FORANE. Manifestations of such reactions have included hypotension, rash, difficulty breathing and cardiovascular collapse

5.5 Abortions

5.5 Abortions Increased blood loss comparable to that seen with halothane has been observed in patients undergoing abortions.

5.6 QT Prolongation

5.6 QT Prolongation QT prolongation, with rare instances of torsade de pointes, have been reported. Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval).

5.7 Interactions with Desiccated Carbon Dioxide Absorbents

5.7 Interactions with Desiccated Carbon Dioxide Absorbents FORANE, like some other inhalational anesthetics, can react with desiccated carbon dioxide (CO 2) absorbents to produce carbon monoxide, which may result in elevated levels of carboxyhemoglobin in some patients. Barium hydroxide lime and soda lime become desiccated when fresh gases are passed through the CO 2 absorber canister at high flow rates over many hours or days.

When a clinician suspects that CO 2 absorbent may be desiccated, it should be replaced before the administration of FORANE. The color indicator of most CO 2 absorbents does not necessarily change as a result of desiccation. Therefore, the lack of significant color change should not be taken as assurance of adequate hydration of the CO 2 absorbent material.

CO 2 absorbents should be replaced routinely regardless of the state of color indicator following current manufacturer’s guidelines for use of anesthesiology equipment.

5.8 Pediatric Neurotoxicity

5.8 Pediatric Neurotoxicity Published animal studies demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 hours. The clinical significance of these findings is not clear.

However, based on the available data, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately three years of age in humans [see Use in Specific Populations (8.1, 8.4), Nonclinical Toxicology (13.2)]. Some published studies in children suggest that similar deficits may occur after repeated or prolonged exposures to anesthetic agents early in life and may result in adverse cognitive or behavioral effects.

These studies have substantial limitations, and it is not clear if the observed effects are due to the anesthetic/sedation drug administration or other factors such as the surgery or underlying illness. Anesthetic and sedation drugs are a necessary part of the care of children needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other.

Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks.

5.9 Laboratory Tests

5.9 Laboratory Tests Transient increases in BSP retention, blood glucose and serum creatinine with decrease in BUN, serum cholesterol and alkaline phosphatase have been observed.

Drug interactions

Drug interactions (US label) US FDA label
  • • Concomitant use of N 2 O and/or opioids reduces the MAC of FORANE. Adjust dose accordingly. (7.1, 7.2)
  • • FORANE decreases the doses of neuromuscular blocking agents required. Adjust dose accordingly. (7.3)
7.1 Opioids

7.1 Opioids Opioids decrease the Minimum Alveolar Concentration (MAC) of FORANE. Opioids such as fentanyl and its analogues, when combined with FORANE, may lead to a synergistic fall in blood pressure and respiratory rate.

7.2 Nitrous Oxide

7.2 Nitrous Oxide Nitrous oxide decreases the MAC of FORANE [see Dosage and Administration (2.1)].

7.3 Neuromuscular Blocking Agents

7.3 Neuromuscular Blocking Agents FORANE potentiates the muscle relaxant effect of all neuromuscular blocking agents and decreases the required doses of neuromuscular blocking agents. In general, anesthetic concentrations of FORANE at equilibrium reduce the ED 95 of succinylcholine, atracurium, pancuronium, rocuronium and vecuronium by approximately 25 to 40% or more compared to N 2 O/opioid anesthesia.

If added relaxation is required, supplemental doses of neuromuscular blocking agents may be used.

7.4 Adrenaline

7.4 Adrenaline FORANE is similar to sevoflurane in the sensitization of the myocardium to arrhythmogenic effect of exogenously administered adrenaline. Doses of adrenaline greater than 5mcg/kg, when administered submucosally may produce multiple ventricular arrhythmias.

7.5 Calcium Antagonists

7.5 Calcium Antagonists FORANE may lead to marked hypotension in patients treated with calcium antagonists.

7.6 Concomitant Use with Beta Blockers

7.6 Concomitant Use with Beta Blockers Concomitant use of beta blockers may exaggerate the cardiovascular effects of inhalational anesthetics, including hypotension and negative inotropic effects.

7.7 Concomitant Use with MAO Inhibitors

7.7 Concomitant Use with MAO Inhibitors Concomitant use of MAO inhibitors and inhalational anesthetics may increase the risk of hemodynamic instability during surgery or medical procedures.

Adverse reactions

Adverse reactions (US label) US FDA label
  • Most common adverse reactions (incidence ≥ 5%) are agitation, cough, breath holding, nausea, chills/shivering, vomiting, laryngospasm, delirium. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Baxter Healthcare Corporation at 1-800-262-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience The following adverse reactions were identified from controlled clinical trials of adult and pediatric subjects exposed to FORANE. The trials were conducted using a variety of pre-medications, other anesthetics, and surgical procedures of varying lengths. The most serious reported adverse reactions in alphabetical order are agitation, arrhythmia, breath holding, elevated liver enzyme, hypotension and laryngospasm.

The most frequent adverse reactions (incidence ≥ 5%) described in Table 1 are agitation, breath holding, chills/shivering, cough, delirium, laryngospasm, nausea, and vomiting. Adverse reactions with an incidence between 1% and 5% are provided in Table 2. Adverse reactions with an incidence less than 1% are provided in Table 3.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Table 2: Adverse Reactions ≥ 5% System Organ Class (SOC) Adverse Reaction Frequency PSYCHIATRIC DISORDERS Delirium 6.2% (N=2830) NERVOUS SYSTEM DISORDERS Agitation (Excitement) Induction 51.8% (N=515) Represents patients not receiving intravenous agents or neuromuscular blocking agents for intubation (i.e., patients receiving inhalation induction).

RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS Breath holding Induction 23.9% (N=515) Cough Induction 28.2% (N=515) Laryngospasm Induction 8.0% (N=515) GASTROINTESTINAL DISORDERS Nausea Recovery 15.4 % (N=2830) Vomiting Recovery 9.5% (N=2830) GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONS Chills/shivering 14.0% (N=1691) Reflects the number of patients with recorded body temperature measurements. Table 3: Adverse Reactions between 1% and 5% System Organ Class (SOC) Adverse Reaction Frequency NERVOUS SYSTEM DISORDERS Movement Maintenance 1.8% (N=2830) CARDIAC DISORDERS Ventricular arrhythmia (Intraoperative) Induction 2.1% (N=2161) Maintenance 2.7% (N=2253) Nodal arrhythmia (Intraoperative) Induction 4.0% (N=2161) Maintenance 1.7% (N=2253) Atrial arrhythmia (Intraoperative) Induction 1.6% (N=2161) Maintenance 2.2% (N=2253) Arrhythmia (Postoperative) 1.1% (N=2830) RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS Breath holding Maintenance 1.1% (N=359) Represents patients not receiving intravenous agents or neuromuscular blocking agents for intubation (i.e., patients receiving inhalation induction).

Cough Maintenance 4.2 % (N=359) Table 4: Adverse Reactions less than 1% System Organ Class (SOC) Adverse Reaction Frequency PSYCHIATRIC DISORDERS Mood changes 0.3% (N=2830) Nightmare 0.4% (N=2175) Reflects the number of patients interviewed by a physician in the recovery period. NERVOUS SYSTEM DISORDERS Convulsive pattern on electroencephalogram 0.5% (N=200) Reflects the number of recorded electroencephalograms.

Seizure 0.04% (N=2830) VASCULAR DISORDERS Hypotension Postoperative 0.3% (N=2830) Hypertension Postoperative 0.1% (N=2830) RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS Laryngospasm Maintenance 0.8% (N=359) Represents patients not receiving intravenous agents or neuromuscular blocking agents for intubation (i.e., patients receiving inhalation induction). Secretions Induction 0.2% (N=515) Maintenance 0.0% (N=359) GASTROINTESTINAL DISORDERS Vomiting Induction 0.8% (N=515) Retching Induction 1.0% (N=515) Maintenance 0.8% (N=359) SKIN AND SUBCUTANEOUS TISSUE DISORDERS Diaphoresis Induction 0.2% (N=515) Maintenance 0.0% (N=359) The following adverse reactions (see Table 5) were observed, but due to limited data, frequency could not be determined.

Table 5: Adverse Reactions with Unknown Frequency System Organ Class (SOC) Adverse Reaction Metabolism and Nutrition Disorders: Blood glucose increased Psychiatric Disorders: Confused state, Nervousness Nervous System Disorders: Ataxia; Dizziness; Drowsiness; Intellectual function decrease Vascular Disorders: Hypotension (Intraoperative); Hypertension (Intraoperative) Hepatobiliary Disorders: Blood bilirubin increased; Bromsulphthalein clearance decreased; Alanine aminotransferase increased; Aspartate aminotransferase increased; Blood alkaline phosphatase increased; Blood lactate dehydrogenase increased Musculoskeletal, Connective Tissue and Bone Disorders: Myalgia General Disorders and Administrative Site Conditions: Asthenia; Fatigue

6.2 Post-Marketing Experience

6.2 Post-Marketing Experience The following adverse reactions have been identified during post-approval use of FORANE. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Post-marketing adverse reactions are listed by MedDRA System Organ Class (SOC), then by preferred term in order of decreasing severity.

BLOOD AND LYMPHATIC SYSTEM DISORDERS: Carboxyhemoglobin increased IMMUNE SYSTEM DISORDERS: Anaphylactic reaction METABOLISM AND NUTRITION DISORDERS: Hyperkalemia in patients with underlying myopathies PSYCHIATRIC DISORDERS: Withdrawal syndrome (following multi-day exposure; symptoms include seizure, hallucination, ataxia, agitation, confusion) NERVOUS SYSTEM DISORDERS: Brain edema, Intracranial pressure increased, Migraine, Myoclonus, Nystagmus, Pupils unequal, Headache CARDIAC DISORDERS: Cardiac arrest, Ventricular fibrillation, Torsade de pointes, Myocardial infarction, Myocardial ischemia, Atrioventricular block complete, Atrioventricular block second degree, Atrial fibrillation, Electrocardiogram QT prolonged, Atrioventricular block first degree, Ventricular tachycardia, Ventricular extrasystoles, Tachycardia, Bradycardia, Cardiac output decreased VASCULAR DISORDERS: Flushing RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERS: Apnea, Hypoxia, Bronchospasm, Airway obstruction, Respiratory depression, Hypercapnia, Stridor, Hiccough GASTROINTESTINAL DISORDERS: Pancreatitis HEPATOBILIARY DISORDERS: Hepatic necrosis, Hepatic failure, Hepatitis fulminant, Cholestatic hepatitis, Hepatitis, Hepatic steatosis, Jaundice, Gamma-glutamyltransferase increased SKIN AND SUBCUTANEOUS TISSUE DISORDERS: Rash MUSCULOSKELETAL, CONNECTIVE TISSUE AND BONE DISORDERS: Rhabdomyolysis RENAL AND URINARY DISORDERS: Acute renal failure**, Oliguria** GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS: Malignant hyperthermia, hypothermia INJURY, POISONING, AND PROCEDURAL COMPLICATIONS *: Unwanted awareness during anesthesia; Dyspnea, Bronchospasm, Stridor, Cough, Dizziness, Paresthesia, Hepatic reactions, Flushing, Rash, Contact dermatitis, Erythema, Periorbital edema, Eye irritation, Conjunctival hyperemia, Headache *All reactions categorized within this SOC, with the exception of, Unwanted awareness during anesthesia, were from occupational exposure in non-patients. **Cases of acute renal failure and oliguria have been reported after isoflurane anesthesia. These events may be secondary to hypotension or other effects of isoflurane.

Adverse reaction frequency tables (US label) US FDA label
Table 2: Adverse Reactions ≥ 5%
System Organ Class (SOC)Adverse ReactionFrequency
PSYCHIATRIC DISORDERSDelirium6.2% (N=2830)
NERVOUS SYSTEM DISORDERSAgitation (Excitement)Induction51.8% (N=515)Represents patients not receiving intravenous agents or neuromuscular blocking agents for intubation (i.e., patients receiving inhalation induction).
RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERSBreath holdingInduction23.9% (N=515)
CoughInduction28.2% (N=515)
LaryngospasmInduction8.0% (N=515)
GASTROINTESTINAL DISORDERSNauseaRecovery15.4 % (N=2830)
VomitingRecovery9.5% (N=2830)
GENERAL DISORDERS AND ADMINISTRATIVE SITE CONDITIONSChills/shivering14.0% (N=1691)Reflects the number of patients with recorded body temperature measurements.
Table 3: Adverse Reactions between 1% and 5%
System Organ Class (SOC)Adverse ReactionFrequency
NERVOUS SYSTEM DISORDERSMovementMaintenance1.8% (N=2830)
CARDIAC DISORDERSVentricular arrhythmia (Intraoperative)Induction2.1% (N=2161)
Maintenance2.7% (N=2253)
Nodal arrhythmia (Intraoperative)Induction4.0% (N=2161)
Maintenance1.7% (N=2253)
Atrial arrhythmia (Intraoperative)Induction1.6% (N=2161)
Maintenance2.2% (N=2253)
Arrhythmia (Postoperative)1.1% (N=2830)
RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERSBreath holdingMaintenance1.1% (N=359)Represents patients not receiving intravenous agents or neuromuscular blocking agents for intubation (i.e., patients receiving inhalation induction).
CoughMaintenance4.2 % (N=359)
Table 4: Adverse Reactions less than 1%
System Organ Class (SOC)Adverse ReactionFrequency
PSYCHIATRIC DISORDERSMood changes 0.3% (N=2830)
Nightmare0.4% (N=2175)Reflects the number of patients interviewed by a physician in the recovery period.
NERVOUS SYSTEM DISORDERSConvulsive pattern on electroencephalogram0.5% (N=200)Reflects the number of recorded electroencephalograms.
Seizure0.04% (N=2830)
VASCULAR DISORDERSHypotensionPostoperative0.3% (N=2830)
HypertensionPostoperative0.1% (N=2830)
RESPIRATORY, THORACIC, AND MEDIASTINAL DISORDERSLaryngospasmMaintenance0.8% (N=359)Represents patients not receiving intravenous agents or neuromuscular blocking agents for intubation (i.e., patients receiving inhalation induction).
SecretionsInduction0.2% (N=515)
Maintenance0.0% (N=359)
GASTROINTESTINAL DISORDERSVomitingInduction0.8% (N=515)
RetchingInduction1.0% (N=515)
Maintenance0.8% (N=359)
SKIN AND SUBCUTANEOUS TISSUE DISORDERSDiaphoresisInduction0.2% (N=515)
Maintenance0.0% (N=359)
Table 5: Adverse Reactions with Unknown Frequency
System Organ Class (SOC)Adverse Reaction
Metabolism and Nutrition Disorders:Blood glucose increased
Psychiatric Disorders:Confused state, Nervousness
Nervous System Disorders:Ataxia; Dizziness; Drowsiness; Intellectual function decrease
Vascular Disorders:Hypotension (Intraoperative); Hypertension (Intraoperative)
Hepatobiliary Disorders:Blood bilirubin increased; Bromsulphthalein clearance decreased; Alanine aminotransferase increased; Aspartate aminotransferase increased; Blood alkaline phosphatase increased; Blood lactate dehydrogenase increased
Musculoskeletal, Connective Tissue and Bone Disorders:Myalgia
General Disorders and Administrative Site Conditions:Asthenia; Fatigue

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, embryofetal toxicity was noted in pregnant mice exposed to 0.075% (increased post implantation losses) and 0.3% isoflurane (increased post implantation losses and decreased livebirth index) during organogenesis.

Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans (see Data).

The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data Animal Data Pregnant rats were exposed to isoflurane at concentrations of 0%, 0.1%, or 0.4% for two hours per day during organogenesis (Gestational Days 6-15). Isoflurane did not cause malformations or clear maternal toxicity under these conditions. Pregnant mice exposed to isoflurane at concentrations of 0%, 0.075%, or 0.30% for 2 hours per day during organogenesis (Gestational Days 6-15).

Isoflurane increased fetal toxicity (higher post implantation losses at 0.075 and 0.3% groups and significantly lower live-birth index in the 0.3% isoflurane treatment group). Isoflurane did not cause malformations or clear maternal toxicity under these conditions. Pregnant rats were exposed to concentrations of isoflurane at 0%, 0.1%, or 0.4% for 2 hours per day during late gestation (GD 15-20).

Animals appeared slightly sedated during exposure. No adverse effects on the offspring or evidence of maternal toxicity were reported. This study did not evaluate neurobehavioral function including learning and memory in the first generation (F1) of pups. In a published study in primates, administration of an anesthetic dose of ketamine for 24 hours on Gestation Day 122 increased neuronal apoptosis in the developing brain of the fetus.

In other published studies, administration of either isoflurane or propofol for 5 hours on Gestation Day 120 resulted in increased neuronal and oligodendrocyte apoptosis in the developing brain of the offspring. With respect to brain development, this time period corresponds to the third trimester of gestation in the human.

The clinical significance of these findings is not clear; however, studies in juvenile animals suggest neuroapoptosis correlates with long-term cognitive deficits [see Warnings and Precautions (5.8), Nonclinical Toxicology (13.2)].

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Induction of and recovery from isoflurane anesthesia are rapid. Isoflurane has a mild pungency which limits the rate of induction, although excessive salivation or tracheobronchial secretions do not appear to be stimulated. Pharyngeal and laryngeal reflexes are readily obtunded. The level of anesthesia may be changed rapidly with isoflurane.

Isoflurane is a profound respiratory depressant. As anesthetic dose is increased, tidal volume decreases and respiratory rate is unchanged. This depression is partially reversed by surgical stimulation, even at deeper levels of anesthesia. Isoflurane evokes a sigh response reminiscent of that seen with diethyl ether and enflurane, although the frequency is less than with enflurane.

Blood pressure decreases with induction of anesthesia but returns toward normal with surgical stimulation. Progressive increases in depth of anesthesia produce corresponding decreases in blood pressure. Nitrous oxide diminishes the inspiratory concentration of isoflurane required to reach a desired level of anesthesia and may reduce the arterial hypotension seen with isoflurane alone.

Heart rhythm is remarkably stable. With controlled ventilation and normal PaCO2, cardiac output is maintained despite increasing depth of anesthesia, primarily through an increase in heart rate which compensates for a reduction in stroke volume. The hypercapnia which attends spontaneous ventilation during isoflurane anesthesia further increases heart rate and raises cardiac output above awake levels.

Muscle relaxation is often adequate for intra-abdominal operations at normal levels of anesthesia. Complete muscle paralysis can be attained with small doses of neuromuscular blocking agents. ALL COMMONLY USED NEUROMUSCULAR BLOCKING AGENTS ARE MARKEDLY POTENTIATED WITH ISOFLURANE, THE EFFECT BEING MOST PROFOUND WITH THE NONDEPOLARIZING TYPE.

Neostigmine reverses the effect of nondepolarizing neuromuscular blocking agents in the presence of isoflurane. All commonly used neuromuscular blocking agents are compatible with isoflurane. Isoflurane can produce coronary vasodilation at the arteriolar level in selected animal models; the drug is probably also a coronary dilator in humans.

Isoflurane, like some other coronary arteriolar dilators, has been shown to divert blood from collateral dependent myocardium to normally perfused areas in an animal model (“coronary steal”). Clinical trials to date evaluating myocardial ischemia, infarction and death as outcome parameters have not established that the coronary arteriolar dilation property of isoflurane is associated with coronary steal or myocardial ischemia in patients with coronary artery disease.

Pharmacokinetics

Half-life and elimination (verbatim, US label)

In the postanesthesia period, only 0.17% of the isoflurane taken up can be recovered as urinary metabolites.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Isoflurane undergoes minimal biotransformation in man. In the postanesthesia period, only 0.17% of the isoflurane taken up can be recovered as urinary metabolites.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Isoflurane 100 mL Bottle₱649.44–₱1,852.00Reference ₱649.44per bottleDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Isoflurane
PNF listingInhalation: 100 mL and 250 mL bottleRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. FORANE · Baxter Healthcare Corporation [US FDA-approved label, version 14, December 9, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d30eb8d-a62e-475f-926b-78ba63bee9c8
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .